Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Papillary renal cell carcinoma, sporadic 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × GSK 1363089 × Clear all
NCT01147484 2023-08-04

IND197

Canadian Cancer Trials Group

Phase 2 Completed
47 enrolled
Breast

Breast Neoplasms

NCT00726323 2017-12-11

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

GlaxoSmithKline

Phase 2 Completed
74 enrolled 14 charts
Genitourinary

Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT00725764 2017-10-16

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

GlaxoSmithKline

Phase 2 Completed
14 enrolled 14 charts
Head & Neck

Head and Neck Neoplasms

NCT00725712 2017-08-24

Study of GSK1363089 in Metastatic Gastric Cancer

GlaxoSmithKline

Phase 2 Completed
74 enrolled 22 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡